ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth

Equity

Direct

Sector - Healthcare

NAV as on 10-02-2025

₹ 17.07

-0.2%

1D

Inception Returns

18.7%

/yr

About ITI Pharma and Healthcare Fund Direct Growth

ITI Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 November, 2021. The fund is managed by . The fund could potentially beat inflation in the long-run.

Key Parameters

  1. ITI Pharma and Healthcare Fund Direct Growth has ₹217 Cr worth of assets under management (AUM) as on Nov 2024 and is less than category average.
  2. The fund has an expense ratio 0.5.

Returns

ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 18.74% since inception. Over the last 1 and 3 years the fund has given a CAGR return of 25.44% and 21.87% respectively.

Holdings

ITI Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Industrial. Its top holdings are Sun Pharmaceuticals Industries Ltd, Lupin Ltd, Apollo Hospitals Enterprise Ltd, Divi's Laboratories Ltd, Suven Pharmaceuticals Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of ITI Pharma and Healthcare Fund Direct Growth

The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. ITI Pharma and Healthcare Fund Direct Growth has no lock in period.

Historical NAV & Returns

Absolute

zero opening, trading, fund transfer fee
205 people have invested ₹ 14.8L in ITI Pharma and Healthcare Fund Direct Growth in the last three months

ITI Pharma and Healthcare Fund Direct Growth Overview

Expense ratio0.47%
Benchmark
S&P BSE Healthcare PR
AUM₹217 Cr
Inception Date11 November, 2021
Min Lumpsum/SIP₹5000/₹500
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
61.96%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

Trailing Returns

as on (10-Feb-25)

Period
ITI Pharma and Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
-6.5%
-2%
-5.2%
3M
-3.3%
-5.6%
-2.4%
6M
4.6%
-6.8%
3.6%
1Y
25.4%
7.1%
22.9%
3Y
21.9%
12.2%
20.4%

Fund Distribution

as on (30-Nov-24)

  • Equity 93.4%

  • Debt & Cash 6.6%

Mid cap
31.2%

Small cap
30.2%

Large cap
29.2%

Sector Allocation

Dec'24

Nov'24

Oct'24

Health
96.8%
Basic Materials
1.8%
Financial Services
1.4%
All changes are between Sep'24 and Nov'24
Nov'24
Oct'24
Sep'24
Fund Returns
0.77%
0.46%
2.61%
Nifty 500
-0.60%
-6.52%
2.04%
  • This fund’s returns stands at 0.77% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.60% as on Nov'24
  • This fund outperformed Nifty 500 by 1.36% in Nov'24
Parameters
Dec'24
Nov'24
Oct'24
AUM
₹ 230.8 Cr
₹ 208.2 Cr
₹ 208.2 Cr
  • AUM of the fund stands at 230.8 Cr as of Dec'24
  • AUM increased by 22.6 Cr between Dec'24 and Nov'24
Top Stocks bought last month
Torrent Pharmaceuticals Ltd's allocation increased from 1.95% to 3.7%
Torrent Pharmaceuticals Ltd's allocation increased from 1.95% to 3.7%
Max Healthcare Institute Ltd Ordinary Shares's allocation increased from 2.15% to 3.53%
Max Healthcare Institute Ltd Ordinary Shares's allocation increased from 2.15% to 3.53%
Aurobindo Pharma Ltd's allocation increased from 3.94% to 4.85%
Aurobindo Pharma Ltd's allocation increased from 3.94% to 4.85%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 15.6 % to 15.23 %
Sun Pharmaceuticals Industries Ltd's allocation decreased from 15.6 % to 15.23 %
Lupin Ltd's allocation decreased from 6.72 % to 6.02 %
Lupin Ltd's allocation decreased from 6.72 % to 6.02 %
Suven Pharmaceuticals Ltd's allocation decreased from 6.06 % to 5.76 %
Suven Pharmaceuticals Ltd's allocation decreased from 6.06 % to 5.76 %
Cash allocation has gone down from 4.7% to 1.1%
Cash allocation has gone down from 4.7% to 1.1%

Top 3 Sectors in December were Health, Financial Services & Basic Materials

Dec'24
Health
97%
Basic Materials
2%
Financial Services
1%
Nov'24
Health
97%
Financial Services
1%
Basic Materials
1%
Fund
Nov'24
Oct'24
Sep'24
No of Holdings
37
40
39
Top 5 Company Concentration
36.6%
38.6%
39.2%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (15.2%)
Sun Pharmaceuticals Industries Ltd (15.6%)
Sun Pharmaceuticals Industries Ltd (16.3%)
No of Sectors
3
3
2
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (97.3%)
Health (96.7%)
Health (97.2%)
Loading...
We are taking more time than usual
Fund House
ITI Asset Management Limited
Total Schemes
Total AUM
₹9.68K Cr
as on 29-Nov-2024
Address
Naman Midtown “A” Wing, 21st Floor, Senapati Bapat Marg, Elphinstone Road
Phone
022-66214999
Website
mfassist@itiorg.com

ITI Pharma and Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 18.74% since inception which is less than its category average return of 20.15%
Fund Allocations

Fund Allocations

This fund has an allocation of 93.44% in Equity, 0% in Debt and 6.56% in Cash related instruments
AUM size ₹217 Cr

AUM size ₹217 Cr

This fund has AUM of ₹217 Cr which is less than its category average of ₹ 1888 Cr
Expense Ratio 0.47%

Expense Ratio 0.47%

This fund has an expense ratio of 0.47% which is less than its category average expense ratio of 1.38%

Frequently Asked Questions for ITI Pharma and Healthcare Fund Direct Growth

The current NAV of ITI Pharma and Healthcare Fund Direct Growth is ₹17.07 as on 10-Feb-2025.
Existing (Absolute + CAGR) as on 10-Feb-2025.
ITI Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
-6.49%
-6.49%
6 Month Returns
4.59%
4.59%
1 Year Returns
25.44%
25.44%
3 Years Returns
81.02%
21.87%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.47% as on January 2025
₹217 Cr as on January 2025
Sun Pharmaceuticals Industries Ltd(16%), Lupin Ltd(6.34%), Apollo Hospitals Enterprise Ltd(5.03%), Divi's Laboratories Ltd(4.89%), Suven Pharmaceuticals Ltd(4.88%) as on January 2025
Health(90.56%), Basic Materials(2.12%), Industrial(0.76%) as on January 2025
The alpha ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
ITI Pharma and Healthcare Fund Direct Growth
3.24
1.71
-
As on January 2025
The alpha for ITI Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
ITI Pharma and Healthcare Fund Direct Growth
0.93
0.91
-
As on January 2025
The Beta for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
ITI Pharma and Healthcare Fund Direct Growth
0.96
0.87
-
As on January 2025
The sharpe ratio for ITI Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ITI Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
ITI Pharma and Healthcare Fund Direct Growth
17.02
15.68
-
As on January 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.49 as on January 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.14 as on January 2025. It tells the consistency of the fund in generating superior risk-adjusted performance
The Exit load of ITI Pharma and Healthcare Fund Direct Growth is 1%